Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Glutaminase inhibitor

DRUG CLASS:

Glutaminase inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	CB-839 Sensitive: C2 – Inclusion Criteria CB-839 Sensitive : C2	CB-839 Sensitive: C2 – Inclusion Criteria CB-839 Sensitive : C2
NFE2L2 mutation	Solid Tumor	NFE2L2 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Solid Tumor	KEAP1 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Lung Cancer	KEAP1 mutation	Lung Cancer	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
ASNS underexpression	Solid Tumor	ASNS underexpression	Solid Tumor	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3
ASNS deletion	Ovarian Cancer	ASNS deletion	Ovarian Cancer	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
NF1 mutation	Leiomyosarcoma	NF1 mutation	Leiomyosarcoma	IPN60090 Sensitive: C4 – Case Studies IPN60090 Sensitive : C4	IPN60090 Sensitive: C4 – Case Studies IPN60090 Sensitive : C4
ASNS underexpression	Ovarian Cancer	ASNS underexpression	Ovarian Cancer	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D
HIF1A overexpression	Ovarian Cancer	HIF1A overexpression	Ovarian Cancer	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D
HIF1A overexpression	Ovarian Cancer	HIF1A overexpression	Ovarian Cancer	olaparib + CB-839 Sensitive: D – Preclinical olaparib + CB-839 Sensitive : D	olaparib + CB-839 Sensitive: D – Preclinical olaparib + CB-839 Sensitive : D
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D